Developer docs
API playgroundTry for free, no card

Search company profiles

Tramontane Therapeutics

Full company profile

uuid000yxko

Namestring
Tramontane Therapeutics
Legal namestring
Tramontane Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Tramontane Therapeutics is a gene therapy company developing AAV vector-based treatments for prevalent metabolic and neurodegenerative diseases, including Nonalcoholic Steatohepatitis (NASH), Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease. The company was founded in 2019 as a spinout from the Universitat Autònoma de Barcelona (UAB), with scientific leadership from co-founder Fátima Bosch, Ph.D., Professor of Biochemistry and Molecular Biology at UAB. Its core technology centers on adeno-associated virus (AAV) vectors engineered to enable continuous, steady-state expression of therapeutic proteins — most notably native Fibroblast Growth Factor 21 (FGF21) — through a one-time intramuscular administration, eliminating the peak-to-trough pharmacokinetic variability and compliance burden associated with repeatedly-injected recombinant analog products.

The company's lead program is an AAV vector designed to express native FGF21 protein for the treatment of NASH, an indication affecting approximately 17 million people in the United States for which no FDA-approved therapies exist to halt or reverse disease progression. Tramontane's portfolio also includes gene therapy candidates targeting Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease, with efficacy and durability established across multiple validated animal models. On September 6, 2023, Tramontane was acquired by Kriya Therapeutics and now operates as a wholly owned subsidiary within Kriya's Metabolic Disease portfolio.

As a preclinical-stage biotechnology company, Tramontane has had no commercial revenue, no marketed products, and no direct customer relationships. Its business model is research-and-development oriented: advancing gene therapy candidates through preclinical validation toward clinical entry — with Kriya anticipating advancement of the NASH candidate into the clinic by the first half of 2025. Following the acquisition, commercial infrastructure, manufacturing, and pipeline development are subsumed within Kriya Therapeutics, which has raised over $600 million in committed capital and operates facilities in Palo Alto, California and Research Triangle Park, North Carolina.

Short descriptiontext

Tramontane Therapeutics is a preclinical gene therapy company developing AAV vector-based treatments for metabolic and neurodegenerative diseases, including NASH, Type 2 diabetes, obesity, Alzheimer's, and Parkinson's. Founded in 2019 as a UAB spinout and acquired by Kriya Therapeutics in September 2023.

Operating statusenum
Acquired
Ownership categoryenum
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
gene therapy, AAV vector therapy, metabolic disease treatment, neurodegenerative disease therapy, FGF21 protein therapy
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy
No data
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tramontane Therapeutics develops adeno-associated virus (AAV) vector-based gene therapies targeting metabolic and neurodegenerative diseases. Its lead program is an AAV vector designed to express a steady level of native FGF21 protein via one-time intramuscular administration for the treatment of Nonalcoholic Steatohepatitis (NASH). Additional pipeline candidates use AAV vectors to express therapeutic proteins for Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • FGF21 is a clinically-validated biological target in NASH; approximately 20 percent of people with NASH will progress to advanced liver disease over several years or decades
Product overview1 text field

Tramontane Therapeutics is a gene therapy company focused on developing treatments for prevalent neurodegenerative and metabolic diseases using adeno-associated viral (AAV) vectors. The company, spun out from Universitat Autònoma de Barcelona (UAB), was acquired by Kriya Therapeutics in September 2023. Its portfolio includes FGF21 gene therapy programs for NASH (lead program), Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease. The core technology platform uses AAV vectors to express therapeutic proteins with continuous expression for chronic diseases.

Product and service5 records
1FGF21 Gene Therapy Program
CategoryGene Therapy / Biopharmaceutical
Description

Lead program: an adeno-associated virus (AAV) vector designed to express a steady level of native FGF21 protein for treating Nonalcoholic Steatohepatitis (NASH). One-time intramuscular gene therapy enabling continuous expression of native FGF21 with potential for better efficacy, safety, tolerability and pharmacokinetic profile than other products in development.

2Type 2 Diabetes Gene Therapy
CategoryGene Therapy / Biopharmaceutical
Description

Gene therapy candidate for insulin-dependent (Type 2) diabetes, utilizing AAV vectors to express therapeutic proteins for metabolic disease management.

3Obesity Gene Therapy
CategoryGene Therapy / Biopharmaceutical
Description

Gene therapy candidate utilizing AAV vectors to express therapeutic proteins for obesity treatment, with strong efficacy and durability established across multiple validated animal models of obesity.

4Alzheimer's Disease Gene Therapy
CategoryGene Therapy / Biopharmaceutical
Description

Gene therapy candidate for Alzheimer's disease using adeno-associated viral vectors to express therapeutic proteins targeting central disorders associated with impaired cognition.

5Parkinson's Disease Gene Therapy
CategoryGene Therapy / Biopharmaceutical
Description

Gene therapy candidate for Parkinson's disease using AAV vectors to express therapeutic proteins targeting central disorders associated with impaired cognition and behavior.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large pharmaceutical company with a broad AAV gene therapy portfolio across hemophilia, rare diseases, and metabolic indications. Comparable as a broad incumbent with AAV capabilities and resources that dwarf Tramontane/Kriya's, though not focused on Tramontane's specific FGF21 approach.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments primarily for CNS diseases including Parkinson's disease, Huntington's disease, and ALS. Directly comparable on AAV platform technology and on the neurological indications (Parkinson's, Alzheimer's) overlapping with Tramontane's pipeline.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for metabolic and CNS diseases, including programs for Huntington's disease and hemophilia B. Directly comparable to Tramontane on AAV vector technology and therapeutic area breadth across neurological and metabolic indications.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing efruxifermin (EFX), an FGF21 analog, for NASH. Targets the same validated biology as Tramontane's FGF21 gene therapy, though via a recombinant protein rather than one-time AAV delivery — making it the closest mechanistic competitor in the lead indication.

TypeEmerging player
Description

Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other rare diseases. An emerging player in the AAV gene therapy space with comparable platform technology and preclinical/early-clinical stage profile, though focused on different indications.

TypeDirect peer
Description

Developer of resmetirom (Rezdiffra), the first FDA-approved therapy for NASH (approved March 2024). Represents the now-established standard of care in Tramontane's lead indication and a key benchmark against which any new NASH therapy — including AAV-FGF21 — must demonstrate clinical and economic value.

TypeBroad incumbent
Description

Global pharmaceutical company that commercializes Zolgensma, the first FDA-approved AAV gene therapy (for SMA). A broad incumbent with proven AAV manufacturing, regulatory, and commercialization capabilities relevant to Tramontane's chronic disease gene therapy approach, though focused on different therapeutic areas.

TypeEmerging player
Description

Clinical-stage gene therapy company developing AAV-delivered treatments for CNS diseases including frontotemporal dementia, Huntington's disease, and Krabbe disease. An emerging player whose AAV platform and CNS focus overlap with Tramontane's neurological pipeline (Alzheimer's, Parkinson's).

TypeBroad incumbent
Description

Commercial-stage biopharmaceutical company with an AAV gene therapy franchise (Roctavian for hemophilia A) and metabolic disease portfolio. A broad incumbent with established AAV manufacturing, regulatory experience, and metabolic disease commercial infrastructure relevant to Tramontane's NASH ambitions.

TypeDirect peer
Description

Clinical-stage company developing pegozafermin, a long-acting FGF21 analog for NASH and severe hypertriglyceridemia. Directly comparable to Tramontane's lead program in target (FGF21) and indication (NASH), representing a near-term competitive threat with a more clinically advanced profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tramontane Therapeutics

Gene Therapytramontanetx.com

Tramontane Therapeutics is a preclinical gene therapy company developing AAV vector-based treatments for metabolic and neurodegenerative diseases, including NASH, Type 2 diabetes, obesity, Alzheimer's, and Parkinson's. Founded in 2019 as a UAB spinout and acquired by Kriya Therapeutics in September 2023.

What Tramontane Therapeutics does

Tramontane Therapeutics is a gene therapy company developing AAV vector-based treatments for prevalent metabolic and neurodegenerative diseases, including Nonalcoholic Steatohepatitis (NASH), Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease. The company was founded in 2019 as a spinout from the Universitat Autònoma de Barcelona (UAB), with scientific leadership from co-founder Fátima Bosch, Ph.D., Professor of Biochemistry and Molecular Biology at UAB. Its core technology centers on adeno-associated virus (AAV) vectors engineered to enable continuous, steady-state expression of therapeutic proteins — most notably native Fibroblast Growth Factor 21 (FGF21) — through a one-time intramuscular administration, eliminating the peak-to-trough pharmacokinetic variability and compliance burden associated with repeatedly-injected recombinant analog products.

The company's lead program is an AAV vector designed to express native FGF21 protein for the treatment of NASH, an indication affecting approximately 17 million people in the United States for which no FDA-approved therapies exist to halt or reverse disease progression. Tramontane's portfolio also includes gene therapy candidates targeting Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease, with efficacy and durability established across multiple validated animal models. On September 6, 2023, Tramontane was acquired by Kriya Therapeutics and now operates as a wholly owned subsidiary within Kriya's Metabolic Disease portfolio.

As a preclinical-stage biotechnology company, Tramontane has had no commercial revenue, no marketed products, and no direct customer relationships. Its business model is research-and-development oriented: advancing gene therapy candidates through preclinical validation toward clinical entry — with Kriya anticipating advancement of the NASH candidate into the clinic by the first half of 2025. Following the acquisition, commercial infrastructure, manufacturing, and pipeline development are subsumed within Kriya Therapeutics, which has raised over $600 million in committed capital and operates facilities in Palo Alto, California and Research Triangle Park, North Carolina.

Tramontane Therapeutics firmographics

Firmographics
Name
Tramontane Therapeutics
Legal name
Tramontane Therapeutics, Inc.
Website
https://tramontanetx.com
Company type
Private
Founded year
2019
Operating status
Acquired
Short description
Tramontane Therapeutics is a preclinical gene therapy company developing AAV vector-based treatments for metabolic and neurodegenerative diseases, including NASH, Type 2 diabetes, obesity, Alzheimer's, and Parkinson's. Founded in 2019 as a UAB spinout and acquired by Kriya Therapeutics in September 2023.
Ownership category
akta.pro rank

Tramontane Therapeutics industry classification

Industry
Product category
Gene Therapy
NAICS
Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy
  • AAV vector therapy
  • Metabolic disease treatment
  • Neurodegenerative disease therapy
  • FGF21 protein therapy

Where Tramontane Therapeutics is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Markets served

Tramontane Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Tramontane Therapeutics product offering

Product offering

Core offering

Tramontane Therapeutics develops adeno-associated virus (AAV) vector-based gene therapies targeting metabolic and neurodegenerative diseases. Its lead program is an AAV vector designed to express a steady level of native FGF21 protein via one-time intramuscular administration for the treatment of Nonalcoholic Steatohepatitis (NASH). Additional pipeline candidates use AAV vectors to express therapeutic proteins for Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease.

Product overview

Tramontane Therapeutics is a gene therapy company focused on developing treatments for prevalent neurodegenerative and metabolic diseases using adeno-associated viral (AAV) vectors. The company, spun out from Universitat Autònoma de Barcelona (UAB), was acquired by Kriya Therapeutics in September 2023. Its portfolio includes FGF21 gene therapy programs for NASH (lead program), Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease. The core technology platform uses AAV vectors to express therapeutic proteins with continuous expression for chronic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • FGF21 Gene Therapy Program Lead program: an adeno-associated virus (AAV) vector designed to express a steady level of native FGF21 protein for treating Nonalcoholic Steatohepatitis (NASH). One-time intramuscular gene therapy enabling continuous expression of native FGF21 with potential for better efficacy, safety, tolerability and pharmacokinetic profile than other products in development.
  • Type 2 Diabetes Gene Therapy Gene therapy candidate for insulin-dependent (Type 2) diabetes, utilizing AAV vectors to express therapeutic proteins for metabolic disease management.
  • Obesity Gene Therapy Gene therapy candidate utilizing AAV vectors to express therapeutic proteins for obesity treatment, with strong efficacy and durability established across multiple validated animal models of obesity.
  • Alzheimer's Disease Gene Therapy Gene therapy candidate for Alzheimer's disease using adeno-associated viral vectors to express therapeutic proteins targeting central disorders associated with impaired cognition.
  • Parkinson's Disease Gene Therapy Gene therapy candidate for Parkinson's disease using AAV vectors to express therapeutic proteins targeting central disorders associated with impaired cognition and behavior.

Quantifiable outcome

  • FGF21 is a clinically-validated biological target in NASH; approximately 20 percent of people with NASH will progress to advanced liver disease over several years or decades

Companies that use Tramontane Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Tramontane Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Tramontane Therapeutics partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights4 records

Tramontane Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Large pharmaceutical company with a broad AAV gene therapy portfolio across hemophilia, rare diseases, and metabolic indications. Comparable as a broad incumbent with AAV capabilities and resources that dwarf Tramontane/Kriya's, though not focused on Tramontane's specific FGF21 approach.
  • Novartis: Global pharmaceutical company that commercializes Zolgensma, the first FDA-approved AAV gene therapy (for SMA). A broad incumbent with proven AAV manufacturing, regulatory, and commercialization capabilities relevant to Tramontane's chronic disease gene therapy approach, though focused on different therapeutic areas.
  • BioMarin Pharmaceutical: Commercial-stage biopharmaceutical company with an AAV gene therapy franchise (Roctavian for hemophilia A) and metabolic disease portfolio. A broad incumbent with established AAV manufacturing, regulatory experience, and metabolic disease commercial infrastructure relevant to Tramontane's NASH ambitions.

Direct peers

  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments primarily for CNS diseases including Parkinson's disease, Huntington's disease, and ALS. Directly comparable on AAV platform technology and on the neurological indications (Parkinson's, Alzheimer's) overlapping with Tramontane's pipeline.
  • uniQure: Clinical-stage gene therapy company developing AAV-based therapies for metabolic and CNS diseases, including programs for Huntington's disease and hemophilia B. Directly comparable to Tramontane on AAV vector technology and therapeutic area breadth across neurological and metabolic indications.
  • Akero Therapeutics: Clinical-stage biopharmaceutical company developing efruxifermin (EFX), an FGF21 analog, for NASH. Targets the same validated biology as Tramontane's FGF21 gene therapy, though via a recombinant protein rather than one-time AAV delivery — making it the closest mechanistic competitor in the lead indication.
  • Madrigal Pharmaceuticals: Developer of resmetirom (Rezdiffra), the first FDA-approved therapy for NASH (approved March 2024). Represents the now-established standard of care in Tramontane's lead indication and a key benchmark against which any new NASH therapy — including AAV-FGF21 — must demonstrate clinical and economic value.
  • 89bio: Clinical-stage company developing pegozafermin, a long-acting FGF21 analog for NASH and severe hypertriglyceridemia. Directly comparable to Tramontane's lead program in target (FGF21) and indication (NASH), representing a near-term competitive threat with a more clinically advanced profile.

Emerging players

  • Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other rare diseases. An emerging player in the AAV gene therapy space with comparable platform technology and preclinical/early-clinical stage profile, though focused on different indications.
  • Passage Bio: Clinical-stage gene therapy company developing AAV-delivered treatments for CNS diseases including frontotemporal dementia, Huntington's disease, and Krabbe disease. An emerging player whose AAV platform and CNS focus overlap with Tramontane's neurological pipeline (Alzheimer's, Parkinson's).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Tramontane Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tramontane Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Tramontane Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tramontane Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tramontane Therapeutics

What does Tramontane Therapeutics do?

Tramontane Therapeutics develops adeno-associated virus (AAV) vector-based gene therapies targeting metabolic and neurodegenerative diseases. Its lead program is an AAV vector designed to express a steady level of native FGF21 protein via one-time intramuscular administration for the treatment of Nonalcoholic Steatohepatitis (NASH). Additional pipeline candidates use AAV vectors to express therapeutic proteins for Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease.

Is Tramontane Therapeutics a public or private company?

Tramontane Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Tramontane Therapeutics founded?

Tramontane Therapeutics was founded in 2019.

Where is Tramontane Therapeutics based?

Tramontane Therapeutics is headquartered in Barcelona, Spain, in the Europe region.

Who are Tramontane Therapeutics's main competitors?

Broad incumbents on record are Pfizer, Novartis and BioMarin Pharmaceutical. Direct peers are Voyager Therapeutics, uniQure, Akero Therapeutics, Madrigal Pharmaceuticals and 89bio. Emerging players are Solid Biosciences and Passage Bio.

Does Tramontane Therapeutics have an API?

No public API is recorded for Tramontane Therapeutics.

What industry is Tramontane Therapeutics in?

Tramontane Therapeutics's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 5417 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireKriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent DiseasesKriya Therapeutics acquired Tramontane Therapeutics, a gene therapy company, and now owns its FGF21 program. The program uses a one-time intramuscular AAV vector to express native FGF21, targeting NASH, with clinical advancement anticipated by H1 2025.KriyatherapeuticsKriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent DiseasesKriya Therapeutics announced on September 6, 2023 that it acquired Tramontane Therapeutics, a private gene therapy company spun out of Universitat Autònoma de Barcelona, as a wholly owned subsidiary. The deal includes Tramontane's lead AAV vector program expressing native FGF21 protein, a target Kriya prioritized for NASH. Kriya expects to advance its NASH gene therapy candidate into the clinic by the first half of 2025.GlobeNewswireKriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent DiseasesKriya Therapeutics, Inc. has acquired Tramontane Therapeutics, Inc. to advance its gene therapy program targeting Nonalcoholic Steatohepatitis (NASH). The acquisition includes Tramontane’s portfolio of Fibroblast Growth Factor 21 (FGF21) assets, with an AAV gene therapy designed for better treatment outcomes in NASH. Kriya aims to initiate clinical trials for this therapy by the first half of 2025.BioSpaceKriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent DiseasesKriya Therapeutics has acquired Tramontane Therapeutics, gaining its lead FGF21 gene therapy program focused on treating Nonalcoholic Steatohepatitis (NASH). The company aims to advance this candidate into clinical trials by the first half of 2025. This acquisition aligns with Kriya's strategy to expand its metabolic disease portfolio using one-time intramuscular AAV gene therapies.